From Detection to Direction: Signatera MRD testing and its impact in CRC

Using ctDNA to Inform Treatment in MIBC

Discover how personalized ctDNA testing is transforming care for patients with muscle-invasive bladder cancer (MIBC). This 30-minute webinar includes results from two landmark Phase 3 studies—IMvigor0

Beyond the Image: New Opportunities in Gynecologic Cancer Testing

Natera hosted esteemed speakers Kathleen Moore, MD, Thomas J. Herzog, MD, and Stephanie Lheureux, MD, PhD, for an interesting discussion on the value of MRD in gynecologic oncology

Building the Evidence for ctDNA as a Surrogate Endpoint in Oncology Drug Development

Kyle Colon Cancer Testimonial

Optimizing Breast Cancer Surveillance: A team approach with MRD testing

Advancing GYN Oncology Care Using ctDNA Monitoring with Signatera™: Clinical Insights and Real-World Application

Leadership at Diagnosis: Quarterbacking the Path to Precision Care

Target, Track, Treat: Optimizing GI Cancer Management with Molecular Residual Disease Testing

Meet Anj, Breast Cancer Survivor and Signatera Patient

Meet Holly, Clear Cell Ovarian Cancer Survivor and Signatera Patient

Clear cell ovarian cancer can return—even years after treatment. #Signatera, Natera’s personalized MRD (ctDNA) test, looks for tiny traces of tumor DNA between scans and may detect molecular signs mon

New data from ASCO 2025 & clinical performance of Natera’s ultra-sensitive MRD platform

ctDNA monitoring with Signatera: An overview for transplant providers

MRD in a minute: Marcus Noel, MD

MRD in a minute: Marcus Noel, md

MRD in a minute: Saum Ghodoussipour, MD

MRD in a minute: Saum Ghodoussipour, md

MRD in a minute: John Sfakianos, MD

MRD in a minute: John Sfakianos, md